Last edition
News about "Eric Hughes"
Teva Wins US FDA Approval for Monthly Olanzapine Injection
Teva has announced US FDA approval of WELTRUZA for ER injectable suspension, as the first and only once-monthly subcutaneous injectable polanzapine for adults.
Eric Hughes | 12/10/2026 | By News Bureau
Teva Reports Ecopipam Data in Pediatric Tourette Syndrome
Teva Pharmaceuticals has reported new ecopipam data showing clinically meaningful tic reduction in about 70 percent of pediatric Tourette Syndrome patients within 8 weeks.
Eric Hughes | 05/10/2026 | By News Bureau
Teva's Olanzapine LAI Shows Long-Term Schizophrenia Efficacy
Teva’s TEV-’749 olanzapine LAI showed high stabilisation rates, low relapse and long-term remission in a phase 3 SOLARIS trial analysis.
Eric Hughes | 22/09/2026 | By News Bureau
Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease
Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.
Eric Hughes | 03/09/2026 | By News Bureau | 139
Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study
Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.
Eric Hughes | 18/02/2026 | By News Bureau | 500
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy